What does the Chronic Disease Co-Care Scheme actually cost? Screening has a cap, treatment does not, and what 1,182 service points really charge, 2026

TL;DR The screening phase has a cap written into the official documents. The treatment phase does not. The official page says, word for word, "Cardiovascular Disease Risk Factor Screening: not more than $120", while for the treatment phase the same page says only "The Government recommended co-payment fee is $150" — recommended is not a cap. On the published list, treatment-phase co-payments run from $0 to $800, and not one service point charges above the screening cap.

---

#Screening has a cap; treatment does not

This is the sentence in this article with the most practical consequence: if you assume the $120 screening cap protects you all the way into the treatment phase, you will get your annual cost wrong, and possibly wrong by a multiple.

The official subsidy and co-payment page sets out both phases on one page, in different words. The screening phase says "not more than"; the treatment phase says "recommended" [Note 1]. One is a ceiling. The other is a reference figure.

The subsidy and co-payment page, the FAQ page, the three press releases this article read, and the scheme's own published list of co-payments clinic by clinic all set no cap of any kind on the treatment-phase co-payment.

One official sentence covers the whole thing: family doctors may set their own consultation co-payment fee for the screening phase (not more than $120) and for the treatment phase, and may adjust it once a year under an established mechanism [Note 2].

⚠️ The screening phase has a bracket after it saying "not more than $120". The treatment phase has no bracket. That is not an omission; it is the charging structure of the whole scheme.

One wording point needs stating plainly: the press release of 28 August 2025 says "not more than $120" in one place and, where it describes one service point cutting its fee, "the Government-recommended $120" in another. That happens the same way in both language editions, so it is not an artefact of translation. Go by the subsidy and co-payment page's "not more than", and by the actual data below: in practice this $120 operates as a cap.

---

#What 1,182 service points actually charge

Two sets of data, two sources, corroborating each other.

The first is the distribution the Government itself published in press releases. 9 August 2024: of all 718 service points, 473 (two-thirds) would charge a consultation co-payment at or below the Government-recommended level ($150 or less) from 1 September that year. 28 August 2025: the service points charging at $150 or below remain at approximately 65 per cent (617 service points), the median co-payment remains at $150, and the rate of increase for the coming year is 3.1 per cent [Note 3]. The same release states that of the current 971 participating service points, 874 (90 per cent) will keep their existing co-payment unchanged.

The second is the co-payment listed clinic by clinic in the scheme's doctor search today, covering 880 doctors across 1,182 service points.

The distribution runs like this. Treatment phase: 776 service points (65.7%) at $150 or below; the commonest values are $150 (614 points), $50 (114), $300 (103), $200 (96) and $234 (71). Cardiovascular screening: $120 (1,162 points), $100 (15), $80 (2), $0 (3) — not one above $120. Hepatitis B screening: $180 (1,172 points), $160 (9), $150 (1) — not one above $180.

Put the two tables together and they say one thing: "not more than" is real, and "recommended" is real too — but they are two entirely different kinds of constraint.

In the screening phase, none of the 1,182 service points exceeds the cap and the overwhelming majority (98%) charge exactly the cap. In the treatment phase, the same service points charge anywhere from $0 to $800, with the median landing precisely on the Government's recommended $150 — but more than a third sit above it.

The Government does not hide this: the scheme's participant co-payment list sets out both phases clinic by clinic, and the doctor search adds the hepatitis B screening co-payment, participation in other government-subsidised schemes, and any suspension of service. The prices are public. You just have to look them up one by one.

---

#Working one out: the same six consultations, 5.33 times apart

Using figures already quoted. Take a participant in the treatment phase in the "hypertension and/or diabetes" group, in their first year:

• Screening phase, one-off co-payment: $120 (the cap, and what 98% of service points charge)
• Treatment phase: that group gets up to 6 subsidised consultations per personal programme year
  • At the Government-recommended $150: 6 × $150 = $900
  • At the highest on the list, $800: 6 × $800 = $4,800
  • The same 6 subsidised consultations, a difference of $3,900
• Drugs on the specified list: $0
• Laboratory tests: $40 to $130 per test package. How many packages a year is not published in any official document, so this item can only be costed per package, not as an annual total.

First year, screening plus consultations alone: at the recommended level $120 + $900 = $1,020; at the highest level on the list, $120 + $4,800 = $4,920.

The $120 screening portion is almost the same whichever clinic you choose. The consultation portion differs by 5.33 times between the highest and the recommended level (4,800 ÷ 900), or 4.82 times with screening included (4,920 ÷ 1,020).

⚠️ This calculation is not telling you to pick the cheapest clinic — this article recommends none — but to point out that if the only figure you remember is $120, your estimate of the annual cost will be wrong, and the source of the error is a column the Government has left uncapped.

Before you join, the one thing you can do is look up what your chosen doctor's column says in the scheme's doctor search.

---

#The whole fee table

A note on dates, which has to be read. The $196 screening consultation subsidy, the full subsidy of screening tests, the $105 quarterly drug subsidy and the $40–$130 treatment-phase test co-payment range all come from Annex II to the press release of 25 September 2023, now almost three years old. No government press release or scheme page since has restated or amended any of those four figures. Treat them as "the level announced at launch, with no published change since".

By contrast the $166 treatment-phase consultation subsidy was confirmed again in the press release of 26 January 2026, so $166 can be taken as current.

⚠️ The scheme's website carries no page revision date — neither the page content nor the site's footer template has a "revised on" field — so the $120, $180, $150 and $80／$150／$380 on those pages can only be given with a retrieval date.

---

#Three people set the prices

The key to the whole scheme is that "who sets the price" has two different answers in the two phases.

One administrative condition is often overlooked: every participant and every family doctor must join eHealth, so that clinical records can pass between the private and public sectors.

⚠️ If you assumed a government scheme means every clinic charges the same: in the screening phase that is nearly true (a cap, and almost everyone charging it), and in the treatment phase it is not, by a wide margin.

---

#The word "Pilot" was dropped on 13 March 2026, and the official pages have not caught up

This is not insurance and not a clinic promotion. It is the Government buying services from private family doctors on a co-payment basis: the Government pays part, you pay part, and District Health Centres are the entrance.

On 13 March 2026 the Government announced that the Chronic Disease Co-Care Pilot Scheme would be regularised and renamed the Chronic Disease Co-Care Scheme. The same release set out what follows: the first stage of the co-care network runs five years, with a target of around 700,000 participants.

The renaming has been applied unevenly across the official pages:

• The scheme website's home page title is already "Chronic Disease Co-Care Scheme", and the navigation entry that used to read "Introduction to the Chronic Disease Co-Care Pilot Scheme" has been replaced by "Introduction to the Scheme".
• But the FAQ page on the same website still used "Pilot Scheme" throughout on 2 August 2026.

⚠️ If you are searching for information, find two names and wonder whether you are looking at two different schemes: it is one scheme. The Government's own FAQ page not having caught up with the renaming does not mean two schemes exist side by side. The name announced on 13 March 2026 is the current one.

A few terms that recur, defined first. Co-payment — for the same service the Government pays the doctor part and you pay part; your part is the co-payment. Family doctor — the private doctor you choose on joining, who then follows you up. District Health Centre / Station — the scheme's registration entrance and the site of its supporting services. Personal programme year — the 12 months from the day you enter the treatment phase, not a calendar year.

---

#Why does this scheme exist? Start with the "17% hidden patients"

The Government's reason for launching it is put bluntly in the 2023 press release.

The epidemiological premise: as projected in the Department of Health's Population Health Survey 2020-22, around 17 per cent of the population aged 45 to 84 have an underlying condition of diabetes or hypertension [Note 4].

In other words: the scheme is aimed not at people who already know they are ill, but at that 17% who do not know. That premise decided the original eligibility condition directly — you had to be undiagnosed to get in.

The second reason came from the Secretary for Health at the launch ceremony on 13 November 2023: making good use of the healthcare capacity of the private sector will help relieve the pressure on the public healthcare sector, allowing Hong Kong's public system to focus more on caring for the disadvantaged.

The policy basis is the Primary Healthcare Blueprint of December 2022. ⚠️ Neither the scheme website, nor the five government press releases this article actually read, nor the Legislative Council Panel on Health Services paper, cites any ordinance or statutory instrument as the scheme's legal basis — this is an administrative subsidy scheme, not a statutory one. (Scheme documents do mention the Registration of Persons Ordinance (Cap. 177) and the Immigration Ordinance (Cap. 115), but only to define identity documents, not as authority for the scheme itself.)

That decides a good deal of what follows: the scheme's charges, eligibility and name can all be changed by administrative decision, without going through the legislature.

The sequence from 2023 to 2026:

⚠️ If you looked at this scheme a few years ago and think you remember the conditions: between 2024 and 2026 screening gained blood lipids and hepatitis B, an invitation pathway opened for people already diagnosed, and the scheme itself was renamed. Old memory goes out of date fast here.

---

#That $180 for hepatitis B is one-off, but confirming the diagnosis takes six months

Once screening is done, if the result falls within what the scheme covers you move to the treatment phase: continuing follow-up by the same family doctor, a set number of subsidised consultations per personal programme year, plus drugs, tests, nurse clinics and allied health services.

But the hepatitis B screening is not finished in one go. District Health Centre staff arrange a free HBsAg rapid diagnostic test for eligible participants; if the result of the participant's first blood test is positive, the family doctor arranges a second blood test six months later to confirm the diagnosis [Note 5].

⚠️ So the up-to-two consultations covered by that one-off $180 are not simply "one extra visit" — the second is a confirmatory test six months after a positive first result. If you intend to use this pathway to find out whether you have chronic hepatitis B, budget six months for confirmation.

One point few people notice: you can still be screened after entering the treatment phase. An official footnote states that a participant in the treatment phase who meets the screening eligibility for a specified chronic disease may undergo that screening, with the same subsidy and co-payment as the screening phase. So someone who entered the treatment phase for blood pressure can still be screened for hepatitis B at screening-phase rates, if they meet its four conditions.

---

#Which conditions the treatment phase covers, and how many consultations

The scheme covers five situations, not four — "a specific blood sugar level" (prediabetes) is its own management group, with its own limit on consultations.

More than one at once? The official wording is that the maximum is determined by the disease group with the highest number of subsidised visits. So a participant with both hypertension and dyslipidaemia gets 6, not 6 + 4.

Joining both schemes carries two more rules [Note 6]: the family doctor's consultation co-payment under the hepatitis B scheme must be consistent with their level under the CDCC scheme; and where one consultation deals with both chronic hepatitis B and the "three highs", the participant pays only one consultation co-payment.

So two schemes do not become two consultation co-payments. (The same release separately provides that where a family doctor manages both hepatitis B and the "three highs" for the same participant in at least two consultations within a calendar year, the Government gives that doctor an extra $300 a year — a subsidy paid to the doctor, not a charge to the participant.)

⚠️ Once the consultations run out: if actual consultations exceed the subsidised limit, or the participant uses services or drugs the scheme does not cover, those costs are paid by the participant.

The Hepatitis B Co-care Scheme also includes liver cancer screening; the scheme website's resources page carries a separate file of liver ultrasound service locations.

---

#Drugs are free; tests are not

Drugs and tests are handled in exactly opposite ways in the treatment phase.

Drugs: free on the list — but the two documents word it differently, and a reader should know. The subsidy and co-payment page says "no additional payment on receiving drugs under the list of Specified Drugs and/or up to 3 days of drugs for episodic illnesses"; Annex II to the press release of 25 September 2023 adds a qualification in both languages, "basic tier" [Note 7].

⚠️ Annex II's wording implies the drug list has tiers, and that only the basic tier is stated to be free of charge; the subsidy and co-payment page carries no such qualification. Which is the current wording is not stated by either document, and this article does not infer it. In practice: before you collect a medicine, ask whether it is on the list and whether it is basic tier.

The Government pays doctors $105 per quarter and lets them buy at a discount from designated suppliers. Drugs on the list are "$0", not "discounted". Drugs off the list are charged by the doctor. The drug list itself is published as a separate file on the scheme website, and was expanded in August 2024 and again in August 2025.

Tests: not free. Screening-phase tests are fully subsidised with nothing extra to pay; the treatment phase is different — a prescribed co-payment of between $40 and $130, each test package covering 2 to 5 test items.

Nurse clinics and allied health: fixed charges. $80 per nurse clinic attendance, $150 for an optometrist or physiotherapist, $380 for a dietitian or podiatrist. This part applies to the CDCC scheme only, not to the Hepatitis B Co-care Scheme.

Bi-directional referral specialist consultation: $250, plus $20 per drug item if prescribed (each charging unit covering 4 weeks, self-financed drugs excluded).

Services outside the scope: by agreement. A family doctor providing a participant with services outside the scheme's scope may agree an additional charge with them. The published doctor list gives only the screening and treatment co-payments, and does not list charges for anything outside the scheme.

---

#Health care vouchers work here, but they have limits of their own

Two sentences sit side by side on the same official page: the Elderly Health Care Voucher (including the reward under the Pilot Reward Scheme) is applicable to the scheme; medical fee waiver is not applicable to the scheme, including the one-off medicine specialist consultation provided by the Hospital Authority under bi-directional referral [Note 8].

Those two have to be read together. This is the most substantial difference between the scheme and public services.

⚠️ But "applicable" does not mean you can stop thinking about the amount: the voucher has its own eligibility and its own limit, set by the voucher scheme and not shown on this scheme's fee page. Each eligible elderly person (65 or above) receives $2,000 a year, with an accumulation limit of $8,000; unused vouchers carry forward without a time limit, but the account total on 1 January each year cannot exceed the accumulation limit.

Which is to say: participants aged 45 to 64 have no vouchers at all, and participants aged 65 or above get only $2,000 of new voucher a year.

Take the calculation above again: a service point charging $300 a consultation costs $1,800 for six — consultations alone use 90% of one year's new voucher, leaving $200. Add the one-off screening co-payment of up to $120 and $80 remains; any further cost, such as a test co-payment of $40 to $130 a package, goes past the year's new $2,000 and has to come from an earlier balance or out of pocket.

⚠️ If you assumed joining means "everything is covered": what is covered is the drugs on the list. Consultations have a ceiling in number, tests cost $40 to $130 a package, allied health is $80 to $380 an attendance, and anything outside the scope is negotiated separately.

---

#Eligibility comes in three groups, and one of them can only wait to be invited

Three groups of people, two entrances. And one of the three — patients already diagnosed and being followed up by the Hospital Authority — is a pathway opened only recently, and one you cannot apply for yourself.

The conditions the scheme website sets out [Note 9]: Chronic Disease Co-Care Scheme — Hong Kong residents aged 45 or above; and no known medical history of diabetes or hypertension. Hepatitis B Co-care Scheme — four conditions.

⚠️ Note that the four hepatitis B conditions are joined by "and", not "or". All four must hold at once:

"I think I might be at risk" is not one of the conditions.

The FAQ does add something many people will find useful: having had a hepatitis B blood test come back positive does not exclude you, so long as you have never been formally diagnosed with chronic hepatitis B.

⚠️ This list is the scheme's administrative eligibility test, not a clinical risk assessment. Not qualifying does not mean you have no hepatitis B risk, and does not mean you do not need testing — only that you cannot use this scheme's subsidy for it.

The FAQ states eligibility more completely than the enrolment page does: besides the identity document requirement, you must have joined eHealth and registered as a member of a District Health Centre or Station, and then meet any one or more of the following:

Group C is a substantive change to the original design: the statement that "if you are already diagnosed you cannot use this" has not been complete since September 2025. Group C participants go straight into the treatment phase on enrolling; once they have had their first subsidised consultation with their matched family doctor, the Hospital Authority cancels their remaining family medicine clinic appointments for that disease.

But note two boundaries. First, Group C can only wait to be invited, and the clinical criteria the Government has prescribed are not published anywhere on the scheme's public pages. Second, once you are in, you cannot use both sides at once — a participant who chooses to have their diabetes or hypertension treated in the public system must notify the District Health Centre / Station immediately to withdraw from the scheme.

Changing doctor: the screening phase locks you in for 270 days. The FAQ provides that, in the screening phase only, a participant may not change their matched family doctor within 270 days of the date of the first subsidised consultation; changes in the treatment phase are handled case by case by the District Health Centre.

⚠️ If you were thinking of "trying it out": whichever doctor you pick in the screening phase is effectively locked in for 270 days. And that doctor's treatment-phase co-payment is published before you choose, which is worth reading first, because it is what you pay at every follow-up afterwards.

---

#What does the "health incentive" require?

The incentive itself is set out plainly: starting from the second programme year, a participant who achieves the health incentive targets will enjoy a one-off reduction in the co-payment fee of $150 maximum for the first subsidised consultation in the following year of the scheme [Note 10].

Mechanically: if your family doctor charges $150 or less, that consultation is free; if more than $150, you pay the excess above $150. The reduction is fixed at a maximum of $150, and whether you still pay after it depends on what your doctor charges. At a service point charging $300, that consultation still costs $150.

As to what the "health incentive targets" are: the incentive mechanism document on the scheme website's resources page lists a series of behavioural and process requirements — measuring blood pressure monthly and uploading the result, attending follow-up with the family doctor at prescribed intervals, completing the Patient Empowerment Programme, and, for participants with diabetes, completing retinal photography annually. The document comes in several versions by diagnosis.

⚠️ But this cannot be stated flatly. Where the press release of 25 September 2023 describes the incentive on the doctor's side, the Chinese reads "meeting targets in controlling blood glucose and blood pressure", while the corresponding English sentence in the same release is stronger and closer to clinical values [Note 11]. The two language editions differ in force, and this article has not obtained the versions of the mechanism document split by diagnosis.

So this article will not say "you will get it even if control is poor", and will not say "you will not get it" either — ask your doctor.

The basis for the doctor's own incentive: a family doctor must have 70 per cent of the participants in their care meeting targets in controlling blood glucose and blood pressure to receive an incentive payment, calculated at 15 per cent of a prescribed total.

If you were about to give up on recording and follow-up because "I cannot control it anyway": what the document lists is whether you followed the process. What your own treatment target should be is for your doctor to decide on your situation, not for this incentive mechanism.

---

#What figures has the Government published? The steadiest is "about 40 per cent"

The steadiest thing in this table is not the participant count but the "about 40 per cent". From nearly eight thousand in May 2024 (out of about 20,000 screened) to the scale reached by January 2026, the proportion found on screening to have prediabetes, diabetes or hypertension has stayed around 40 per cent.

⚠️ That proportion is larger than the projection the 2023 press release cited (about 17 per cent of the population aged 45 to 84), but the two cannot simply be subtracted: the 17 per cent has as its denominator the population aged 45 to 84 and counts only diabetes and hypertension; the 40 per cent has as its denominator people who volunteered and completed screening (not confined to ages 45 to 84), and its numerator includes prediabetes, and from August 2025 dyslipidaemia as well. Different denominators and different disease definitions: this is not "the detection rate has more than doubled".

That level at end-January 2026 came nearly 10 months ahead of the original target date.

---

#Effectiveness research appears only in fragments, with three limits

The Government publishes participation numbers and the "about 40 per cent" densely; on effectiveness, what is public is fragments inside press releases.

The Government commissioned a local university to conduct research in the first quarter of 2024. Preliminary analysis showed that six months after joining, the average glycated haemoglobin of participants diagnosed with diabetes fell by about 1.0%, and the average systolic blood pressure of participants diagnosed with hypertension fell by about 15.0 mmHg. At 12 months: average glycated haemoglobin among diabetic participants went from 7.8% to 6.7%, and average systolic pressure among hypertensive participants from 150 mmHg to 135 mmHg.

On the questionnaire: the research team recruited 614 participants across 18 District Health Centres and Stations, with overall satisfaction of 82.5 (out of 100) and satisfaction with the first family doctor consultation of 76; 96.1% of hypertensive and 98.0% of diabetic participants said their self-management of health had improved.

Three limits govern how those figures can be read.

First, there is no control group. All of the above compares participants' own averages before and against after; nothing published includes a group that did not join. So these figures cannot be read as "the scheme lowered glycated haemoglobin by 1.1 percentage points" — how much came from the scheme and how much from simply starting to see a doctor and take medicine is a question the published material cannot answer.

Second, satisfaction and improved self-management are self-reported. The 96.1% and 98.0% are participants saying in a questionnaire that they had improved, not an objective measurement. And the denominator of those two percentages is not the 614 respondents as a whole but the hypertensive and diabetic subgroups within it; the press release does not publish the size of either subgroup, so the actual headcounts behind those percentages cannot be worked out.

Third, the full research report, the name of the university responsible and the research method are published in none of the official sources listed at the end — only the press release fragments above.

One other set of figures is of an entirely different kind: on a simulated scenario of 200,000 participants, the scheme is projected to prevent about 9,000 cardiovascular disease cases and 11,000 deaths, gain about 54,000 quality-adjusted life years, and save $2.7 billion in healthcare expenditure.

⚠️ Those four figures are modelled expectations, not observed results, and the release presents them that way itself.

Bi-directional referral is barely used. The Secretary for Health's opening remarks of 10 May 2024 [Note 12]: as at 2 May, of about 8,000 participants found to have hypertension, diabetes or raised blood sugar, 13 participants had been arranged by their family doctor to receive a one-off medicine specialist consultation at the Hospital Authority through the bi-directional referral mechanism; of those 13, assessed as being at more serious risk, two were diagnosed after referral as being at risk of cardiac complications and needing specialist follow-up.

So in the scheme's early period, of about 8,000 participants found to have an abnormality, only 13 — about 0.16% — used bi-directional referral. That is an early figure from May 2024; none of the later official sources listed at the end has updated the usage.

⚠️ If you want to decide whether to join on the question "does it work": the published figures cannot answer it. What they can answer is that about 40 per cent of those screened were found to have something, and that participants' average blood sugar and blood pressure improved after joining — with no control group.

---

#Compared with a Hospital Authority family medicine clinic

The consultation fees are close, but the safety nets are designed in opposite ways: the Hospital Authority has a medical fee waiver and the scheme does not — and the scheme's route for people who qualify for a waiver is to send them back to the Hospital Authority.

The Government has made a comparison of its own, though against the General Out-patient Clinic Public-Private Partnership: the CDCC scheme provides a more comprehensive range of services than the GOPC PPP Programme, for example covering multidisciplinary services, with District Health Centre coordination and other health management courses as supporting arrangements, and a health incentive [Note 13]. The same release states that the Hospital Authority launched the GOPC PPP in 2014, that it now has about 50,000 participants, mainly with diabetes and hypertension, and that it is expected to end in 2028.

The safety net: a route back to the public system. Because the scheme itself does not admit the medical fee waiver, the Government has made a separate arrangement for those who would qualify for one: recipients of Comprehensive Social Security Assistance, recipients of the Old Age Living Allowance aged 75 or above, and holders of a medical fee waiver certificate are arranged by District Health Centres to receive the same screening and management services at designated Hospital Authority family medicine clinics, where the waiver still applies.

For hepatitis B, such people are arranged to receive the same screening and treatment at 18 designated family medicine clinics, with full or partial waiver according to their eligibility. For the "three highs" the arrangement was rolled out in stages: 7 general out-patient clinics in late March 2025, 14 by the end of June 2025, with the aim of covering all 18 districts by the end of 2025.

Two further boundaries: joining the scheme generally does not affect other services you receive from the Hospital Authority or the Department of Health, such as emergency services and other specialist services; but for the diseases the scheme covers, you cannot use both sides at once. And choosing a private doctor who is not in the scheme means paying the whole cost yourself.

⚠️ If you currently receive CSSA, the Old Age Living Allowance at 75 or above, or hold a medical fee waiver certificate: you are not excluded from the service, but your route is not a private clinic. It is a designated Hospital Authority family medicine clinic arranged by a District Health Centre, because that is where the waiver works.

---

#What this scheme does not do

Every item below is something readers assume is there and the official documents do not contain.

• There is no cap on the treatment-phase consultation co-payment. The highest actually on the list is $800.
• Charges for services outside the scheme's scope are not published. The official treatment is that the doctor "may charge the Scheme Participant" by agreement.
• The medical fee waiver does not apply at all, including to the one-off medicine specialist consultation the Hospital Authority provides under bi-directional referral.
• The clinical criteria Group C must meet are not published.
• The scheme website carries no page revision date. So its charges can only be given with a retrieval date, and there is no way to know when they last changed.
• Two names are live on the official pages at once. The FAQ page still used "Pilot Scheme" on 2 August 2026.
• Once the consultations are used up, further follow-ups that year are self-financed, at a rate the doctor sets.
• The Elderly Health Care Voucher is not an unlimited backstop. $2,000 a year, an $8,000 account limit — and participants aged 45 to 64 have none at all.

⚠️ If you were treating this scheme as "chronic disease costs, capped": the only thing capped is the screening, once. Of every cost in the treatment phase, only drugs on the list are certainly $0; consultations, tests, allied health, excess follow-ups and anything outside the scope all have to be costed item by item.

---

#What to do next

1. Before enrolling, look up your chosen doctor's treatment-phase co-payment in the scheme's doctor search. That is what you pay at every follow-up afterwards, and it has no cap.
2. The screening charge does not need shopping around. 1,162 of 1,182 service points charge the full $120, and none charges more.
3. Remember that choosing locks you in for 270 days. In the screening phase you cannot change family doctor within 270 days of the first subsidised consultation.
4. Before collecting a medicine, ask whether it is on the list and whether it is basic tier. On the list it is $0, not discounted; the two official documents word "on the list" differently.
5. Do not treat tests as free. Screening-phase tests are fully subsidised; treatment-phase tests cost $40 to $130 per package.
6. If you receive CSSA, the Old Age Living Allowance at 75 or above, or hold a medical fee waiver certificate, your route is a different one — a designated Hospital Authority family medicine clinic arranged by a District Health Centre, because that is where the waiver works.
7. If you are using the hepatitis B pathway, budget six months for confirmation. A positive first test is confirmed by a second blood test six months later.
8. If you are already diagnosed and followed up by the Hospital Authority, you can only wait to be invited. The criteria are unpublished and you cannot apply yourself.

---

#Frequently asked questions

Is screening always $120?

"Not more than $120" is a cap, not a fixed price. Across the 1,182 service points in the scheme's doctor search, 1,162 charge $120, 15 charge $100, 2 charge $80 and 3 charge $0, and none charges more than $120. Hepatitis B screening works the same way: a cap of $180, and $180 is what almost everyone charges.

What does each treatment-phase consultation cost?

It is set by the family doctor you choose. The Government recommends $150 but sets no cap. Across the 1,182 service points in the doctor search the range is $0 to $800, the median is $150, and 776 (65.7%) are at $150 or below. The Government's release of 28 August 2025 states that 617 of 971 service points charge $150 or below, that the median remains at $150, that the overall rate of increase for the coming year is 3.1 per cent, and that 874 of them (90 per cent) keep their fee unchanged.

Are drugs and tests included?

Drugs on the specified list, and up to three days of drugs for episodic illness, carry "no additional payment" — $0; off the list the doctor charges. Tests depend on the phase: screening-phase tests are fully subsidised with nothing extra to pay, while treatment-phase tests carry a prescribed co-payment, generally $40 to $130 per test package (that range comes from the document of 25 September 2023, with no published change since).

I have already been diagnosed with hypertension. Can I still join?

The screening pathway (Group A) requires no known diagnosis of diabetes or hypertension. But there is also Group C: Hospital Authority family medicine clinic patients from 1 September 2025, and General Out-patient Clinic Public-Private Partnership participants from 1 January 2026, may join if they meet clinical criteria prescribed by the Government and receive an invitation, entering the treatment phase directly; family medicine clinic patients must also have attended there for the relevant disease for 12 months before enrolling. Group C can only wait to be invited, and the criteria are unpublished.

What are the Hepatitis B Co-care Scheme's eligibility conditions?

Besides the requirement common to all participants — having joined eHealth and registered as a member of a District Health Centre or Station — all four of the following must hold at once: a Hong Kong resident born in or before 1988; family members (parents, siblings, offspring) or sexual partners with chronic hepatitis B; no known medical history of chronic hepatitis B nor related symptoms; and not having received a complete course of hepatitis B vaccination. The FAQ adds that having had a positive hepatitis B blood test does not exclude you, so long as you have never been formally diagnosed with chronic hepatitis B. At present enrolment is only at a District Health Centre or Station. Not qualifying does not mean you have no risk — whether you need testing is for a doctor to decide on your situation.

What does the $180 for hepatitis B cover, and when do I get a result?

$180 is a one-off co-payment covering up to two consultations (the Government subsidises the doctor $136 in total for the two), and the HBsAg rapid diagnostic test is free at a District Health Centre. The reason for two consultations is that if the first blood test is positive, the family doctor arranges a second blood test six months later to confirm the diagnosis — so confirmation takes six months.

If I join both the hepatitis B and the chronic disease schemes, do I pay two consultation co-payments?

No. The press release of 26 January 2026 provides that where one consultation deals with both, "the participant only needs to pay one consultation co-payment"; the same release provides that the family doctor's consultation co-payment under the hepatitis B scheme must be consistent with their level under the CDCC scheme. The number of subsidised consultations follows the disease group with the highest number.

Can Elderly Health Care Vouchers cover the co-payments?

Vouchers are applicable to the scheme, but the voucher itself is limited to eligible elderly persons aged 65 or above, at $2,000 a year with an account accumulation limit of $8,000. Participants aged 45 to 64 have no vouchers; those 65 or above are still bound by that limit. The medical fee waiver does not apply to the scheme at all.

Does the health incentive require blood sugar and blood pressure targets?

The incentive is that "starting from the second programme year, a participant who achieves the health incentive targets will enjoy a one-off reduction in the co-payment fee of $150 maximum for the first subsidised consultation in the following year of the scheme". What the incentive mechanism document on the scheme website's resources page lists is process requirements — measuring and uploading blood pressure monthly, attending follow-up at prescribed intervals, completing the Patient Empowerment Programme, and annual retinal photography for participants with diabetes. The reduction is at most $150: if the doctor charges $150 or less that consultation is free, and if the charge is above $150 you pay the excess. Note that where the same press release describes the incentive on the doctor's side, the English is stronger and closer to clinical values, so this is a point to settle with your own doctor.

After joining, can I still go to a public clinic for the same condition?

No. The FAQ provides that a participant who chooses to use the public system to treat their diabetes or hypertension must notify the District Health Centre or Station immediately to withdraw from the scheme. But joining generally does not affect other services you receive from the Hospital Authority or the Department of Health, such as emergency services and other specialist services.

Can I change doctor after choosing one?

Screening phase: you may not change your matched family doctor within 270 days of the date of the first subsidised consultation. Treatment phase: handled case by case by the District Health Centre.

---

#What this article does not state

• The list of screening-phase test items is not set out here. The full list is published as a separate file on the scheme website's resources page, which is not among the sources used here; nor are the specific combinations of fasting glucose, glycated haemoglobin and 24-hour ambulatory blood pressure, nor threshold values such as "LDL ≥ 4.1 mmol/L" — none of which appears on the scheme's public pages.
• How many test packages a year the treatment phase requires is not stated here, and no annual total for tests is calculated.
• The current number of drugs on the specified list after the August 2025 expansion is not set out here. The list is published as a separate file on the scheme website, which is not among the sources used here.
• Whether the scheme's co-payments count towards the Hospital Authority's HK$10,000 annual fee cap is not stated in either direction. None of the official sources listed at the end addresses it. One thing is worth stating plainly so that no reader treats that cap as a backstop for this scheme's costs: on the Authority's own page the cap requires no financial assessment but does not take effect automatically — the four conditions are that you must be an eligible person, that eligible medical fees and charges paid within the year reach HK$10,000, that you have no outstanding balance anywhere in the Authority, and that the hospital services received are not assessed by the Authority as being without clinical need; after reaching it you still have to apply through HA Go or a hospital shroff office, re-apply each calendar year, and meet an application deadline of 31 March of the following year (late applications are not accepted), with self-financed drugs and medical devices outside its scope.
• The clinical criteria Group C must meet are not set out here, because they are not published on the public pages.
• Which of the scheme's charges an Elderly Health Care Voucher may specifically be used against is not stated here. The subsidy and co-payment page says only "applicable to the Scheme", without itemising; the $2,000 a year, $8,000 accumulation limit and age-65 eligibility quoted here come from the voucher scheme's own pages and are the voucher's limits, not this scheme's.
• The prevalence of chronic hepatitis B in the Hong Kong population is not set out here. The "about 7%" that circulates has no source among the material used here.
• Several names appear only in the English texts of the sources used here: Primary Healthcare Blueprint, Primary Healthcare Co-care Network, eHealth (Electronic Health System), Patient Empowerment Programme, Comprehensive Social Security Assistance (CSSA), Old Age Living Allowance (OALA). The Chinese edition of this article gives the English names at first mention for the same reason, and its Chinese renderings of them are explanatory rather than quoted. The term for the General Out-patient Clinic Public-Private Partnership is taken from the wording of the Chinese version of the press release of 28 August 2025.
• The verbatim Chinese text of the renaming announcement of 13 March 2026 is not quoted. That release exists in both languages, and this article reports the facts in the English edition without putting the report inside quotation marks. The same treatment applies to Legislative Council paper CB(4)547/2024(03), the incentive mechanism document, and several items in the FAQ — all three exist in Chinese, but what this article obtained was the English text.
• The reliability of the effectiveness research's method and conclusions is not assessed here. The full report, the name of the university responsible and the research method are all unpublished; the before-and-after comparison published has no control group; and the four figures from the simulated scenario are modelled expectations, not observed results.
• On bi-directional referral this article has only the early figure from May 2024. No later source updates it.
• This article does not assess, rank or recommend any participating family doctor or any clinic, and makes no recommendation on whether to join, whether to take medication, or what a treatment target should be.
• The $196 screening consultation subsidy, the full subsidy of screening tests and the $40–$130 treatment-phase test co-payment all come from the document of 25 September 2023, nearly three years old at the time of writing. No later source restates or amends them, and this article treats them as the level announced at launch with no published change since.

---

#Notes: the official wording

Where a source publishes in English, the wording below is the source's own. Where a source has no English edition, the rendering is ours and is marked as such, with the Chinese original set out alongside so it can be checked.

[Note 1] The subsidy and co-payment page (no revision date on the page; retrieved 2 August 2026). Screening phase:

Scheme Participant will only need to pay a one-off co-payment fee / Cardiovascular Disease Risk Factor Screening : not more than $120 / Hepatitis B Screening : not more than $180

The treatment phase on the same page:

The Government will provide a subsidy for each subsidised consultation, while Scheme Participant will only need to pay the co-payment fee determined by Family Doctor upon enrolment to the Scheme. The Government recommended co-payment fee is $150

[Note 2] The press release of 28 August 2025, handling both phases inside one sentence: family doctors may determine the consultation co-payment fee for the screening phase (not more than $120) and for the treatment phase themselves, and may adjust it once a year under the established mechanism.

[Note 3] The same release on the distribution:

the service points charging the Government-recommended consultation co-payment fees at $150 or below remain at approximately 65 per cent (617 service points), while the median co-payment remains at $150.

Overall, the rate of increase of the consultation co-payment fees for treatment phase is 3.1 per cent in the coming year.

[Note 4] The epidemiological premise, press release of 25 September 2023:

As projected in the Population Health Survey 2020-22 of the Department of Health, around 17 per cent of the population aged 45 to 84 have an underlying condition of DM or HT. In this connection, the Government will roll out the CDCC Pilot Scheme as a move to encourage early prevention and management of chronic diseases.

The scheme's aims, from the introduction page: to provide convenient screening for chronic disease including diabetes and hypertension, together with blood lipid testing, so as to assess and manage cardiovascular risk factors including the "three highs" more comprehensively; to prevent chronic disease early and reduce related complications; and to put into practice the concept of one family doctor for each person.

The official definition of the co-payment model, from the same 2023 release:

The CDCC Pilot Scheme will operate on a co-payment model. Government subsidies will be offered during the screening and treatment phases, while participants being the one who should take the primary responsibility for their own health will have to pay a certain amount of co-payment fees.

[Note 5] The press release of 26 January 2026:

Under the general service workflow, if the result of the participant's first blood test is positive, the family doctor will arrange a second blood test for the participant six months later to confirm the diagnosis.

District Health Centre staff arrange a free HBsAg rapid diagnostic test for eligible participants at the centre.

Screening remains available in the treatment phase, from the footnote to the subsidy and co-payment page: a participant in the treatment phase who meets the screening eligibility for a specified chronic disease may undergo that screening, with the same subsidy and co-payment as in the screening phase.

[Note 6] The two rules for running both schemes, press release of 26 January 2026:

Note: The co-payment fee for medical consultations set by family doctors under the Hepatitis B Co-care Scheme must be consistent with the co-payment level set under the CDCC Pilot Scheme.

The same release provides that where a family doctor deals with both chronic hepatitis B and the "three highs" in one consultation, the participant only needs to pay one consultation co-payment. The disease groups and their subsidised consultations, from the introduction page: hypertension and/or diabetes — up to 6 subsidised consultations per personal programme year; a specific blood sugar level of prediabetes — up to 4; a specified condition of dyslipidaemia only — up to 4 in the first personal programme year and up to 2 a year from the second; chronic hepatitis B — up to 4. For a participant with more than one relevant illness the same page provides:

the maximum number of subsidised visits allotted for a Relevant Illness within each PPY will be determined by the disease group of the Relevant Illness with the highest number of subsidised visits

[Note 7] The drug item, worded differently in two documents. The subsidy and co-payment page:

No additional payment on receiving drugs under the list of Specified Drugs and/or up to 3 days of drugs for episodic illnesses

Annex II to the press release of 25 September 2023 adds a qualification, in both languages:

No additional co-payment fee for drugs under basic tier of the Scheme Drug List

On tests, the same Annex II states that the Government subsidises part of the cost item by item and that the participant pays a prescribed co-payment of between $40 and $130, with each test package covering 2 to 5 test items.

[Note 8] The two payment rules, side by side on the subsidy and co-payment page:

Elderly Health Care Voucher (including the reward under Pilot Reward Scheme) is applicable to the Scheme

Medical fee waiver is not applicable to the Scheme

The charge for a bi-directional referral specialist consultation, from the same page:

Under the bi-directional referral mechanism, each attendance of one-off Medicine specialist consultation provided by HA is charged at a standardised fee of $250. In the event that drug prescription is required, a fee of $20 will be charged for each prescribed drug item [each charging unit covers 4 weeks (excluding self-financed drugs)].

Services outside the scope, from the same page:

Subject to mutual agreement, Family Doctor may charge the Scheme Participant for services outside the service scope of the Scheme

The voucher's own limits, from the Elderly Health Care Voucher Scheme page:

Elderly persons aged 65 or above and holding a valid Hong Kong Identity Card or Certificate of Exemption issued by the Immigration Department, except for those who obtained a Hong Kong Identity Card by virtue of a previous permission to land or remain that has expired or ceased to be valid, are eligible to receive and use the vouchers to pay for private primary healthcare services.

At present, the annual voucher amount for each eligible elderly person is $2,000 while the accumulation limit of vouchers is $8,000.

[Note 9] The enrolment page (no revision date on the page; retrieved 2 August 2026):

"Chronic Disease Co-Care Scheme" Hong Kong residents* aged 45 or above; and No known medical history of diabetes mellitus (DM) or hypertension (HT) "Hepatitis B Co-care Scheme" Hong Kong residents* born in or before 1988 (that is the year of the introduction of universal childhood hepatitis B immunisation programme); and Whose family members (including parents, siblings and offspring) or sexual partners have chronic hepatitis B; and No known medical history of chronic hepatitis B nor related symptoms; and Have not received a complete course of hepatitis B vaccination

The same page defines "Hong Kong residents" as (1) holders of a Hong Kong Identity Card issued under the Registration of Persons Ordinance (Cap. 177), except where the card was obtained by virtue of a permission to land or remain that has expired or ceased to be valid; or (2) holders of a Certificate of Exemption as specified in the Immigration Ordinance (Cap. 115).

[Note 10] The health incentive, from the introduction page:

Starting from the second programme year, Scheme Participant who achieves health incentive targets will enjoy a one-off reduction in co-payment fee by $150 maximum (i.e. the co-payment fee recommended by the Government) for the first subsidised consultation in the following year of the Scheme.

[Note 11] On the doctor's incentive, the press release of 25 September 2023 reads in Chinese as meeting targets in controlling blood glucose and blood pressure, while the corresponding English sentence in the same release is:

achieved the health incentive targets in regulating blood glucose and blood pressure level

The two language editions differ in force, and this article has not obtained the versions of the mechanism document split by diagnosis, so it asserts nothing in either direction about the participant's side of the incentive.

[Note 12] Bi-directional referral, from the Secretary for Health's opening remarks of 10 May 2024. That press release exists in Chinese only — it does not appear on the English index for that date — so the rendering below is ours, with the Chinese original alongside. The correction in round brackets is the speech's own.

As at 2 May, among the approximately 6 000 (should be 8 000) participants found to have hypertension, diabetes or raised blood sugar, 13 participants were arranged by their family doctors to receive a one-off Medicine specialist consultation at the Hospital Authority through the bi-directional referral mechanism. […] Among these 13 members of the public assessed as being at more serious risk, two participants were indeed diagnosed after referral as being at risk of cardiac complications, requiring specialist follow-up treatment to prevent further deterioration. (our translation from the Chinese original)

Chinese original:

截至五月二日，我們在約6 000（應為8 000）名發現患有高血壓、糖尿病或血糖偏高的參加者中，有13名參加者獲其家庭醫生安排透過雙向轉介機制到醫管局接受屬一次性質的內科專科諮詢。[...] 在這13名被評估為有較嚴重風險的市民當中，確實有兩名參加者的病情在轉介後被診斷為有心臟病的併發症風險，需要接受專科跟進治療以防止病情繼續惡化。

[Note 13] The comparison with the General Out-patient Clinic Public-Private Partnership, press release of 28 August 2025:

The CDCC Pilot Scheme provides a more comprehensive range of services to citizens as compared with the GOPC PPP Programme, for example, covering multidisciplinary services (including dedicated nurse clinics, optometrists, podiatrists, physiotherapists and dietitians), with coordination by DHCs and other supporting arrangements such as health management courses, as well as a health incentive.

The Secretary for Health on relieving pressure on the public sector, at the launch ceremony of 13 November 2023, said that making good use of the healthcare capacity of the private sector will help relieve the pressure on the public healthcare sector and allow Hong Kong's public healthcare system to focus more on caring for the disadvantaged.

---

#Sources and dates checked

• Primary Healthcare Commission, "Introduction to the Chronic Disease Co-Care Scheme and the Hepatitis B Co-care Scheme" (the scheme's aims, the screening-phase workflow, disease groups and subsidised consultation numbers, the health incentive provision): https://www.primaryhealthcare.gov.hk/cdcc/tc/gp/introduction.html and https://www.primaryhealthcare.gov.hk/cdcc/en/gp/introduction.html (no revision date on the page; retrieved 2 August 2026)
• Primary Healthcare Commission, "Subsidy and Co-payment" (the screening caps of "not more than $120" and "not more than $180", the recommended $150 for the treatment phase, no additional payment for drugs on the list, $80 for nurse clinics / $150 for optometrists and physiotherapists / $380 for dietitians and podiatrists, $250 plus $20 per drug item for bi-directional referral, the voucher being applicable and the fee waiver not, and the footnote allowing screening during the treatment phase): https://www.primaryhealthcare.gov.hk/cdcc/tc/gp/join_cdcc_co_payment.html and https://www.primaryhealthcare.gov.hk/cdcc/en/gp/join_cdcc_co_payment.html (no revision date on the page; retrieved 2 August 2026)
• Primary Healthcare Commission, "Eligibility" (the conditions of both schemes verbatim, the definition of Hong Kong resident, the enrolment routes): https://www.primaryhealthcare.gov.hk/cdcc/tc/gp/join_cdcc_enrol_now.html and https://www.primaryhealthcare.gov.hk/cdcc/en/gp/join_cdcc_enrol_now.html (no revision date on the page; retrieved 2 August 2026)
• Primary Healthcare Commission CDCC FAQ (the three-group eligibility structure, the eHealth and District Health Centre membership requirements, Group C entering the treatment phase directly and the Hospital Authority cancelling subsequent appointments, the withdrawal rule, a past positive hepatitis B test not excluding participation, the 270-day rule on changing doctor, what the doctor list carries, the deduction mechanism for the health incentive, liver cancer screening within the hepatitis B scheme, and joining not affecting other Hospital Authority or Department of Health services): https://www.primaryhealthcare.gov.hk/cdcc/tc/gp/faq.html and https://www.primaryhealthcare.gov.hk/cdcc/en/gp/faq.html (no revision date on the page; the page still used the "Pilot Scheme" name at the time of retrieval; retrieved 2 August 2026)
• Primary Healthcare Commission, participant co-payment list for the screening and treatment phases (the co-payments of each clinic in both phases): https://www.primaryhealthcare.gov.hk/cdcc/resources/copayment_wef_0901.pdf (the document states co-payments effective 1/9/2025 and an update date of 19/08/2025; retrieved 2 August 2026)
• Primary Healthcare Commission CDCC doctor search (the screening, hepatitis B screening and treatment-phase co-payments at each service point, from which this article's distribution figures were counted): https://www.primaryhealthcare.gov.hk/cdcc/tc/gp/doctor_search.html, data file https://www.primaryhealthcare.gov.hk/cdcc/doctorList/doctorListShort.json (the file carries no date of its own; retrieved 2 August 2026)
• Primary Healthcare Commission CDCC incentive mechanism note (the health incentive targets being process requirements; a Chinese version exists on the same page, and this article reports rather than quotes it): https://www.primaryhealthcare.gov.hk/cdcc/resources/incentive_mechanism_intro_en.pdf (retrieved 2 August 2026)
• Government press release, "Government announces details of Chronic Disease Co-Care Pilot Scheme" (the 17 per cent projection from the Population Health Survey 2020-22, the definition of the co-payment model, the 70 per cent and 15 per cent bases for the doctor's incentive) and its Annex II, "Government subsidy and participant co-payment under the CDCC Pilot Scheme" ($196／$120, tests fully subsidised, $166, the $105 quarterly drug subsidy, the $40–$130 test co-payment, the rule on exceeding the subsidy, and the definition of the personal programme year): https://www.info.gov.hk/gia/general/202309/25/P2023092500476.htm (English) and https://www.info.gov.hk/gia/general/202309/25/P2023092500475.htm (Chinese); Annex II https://gia.info.gov.hk/general/202309/25/P2023092500476_433349_1_1695625141556.pdf (English) and https://gia.info.gov.hk/general/202309/25/P2023092500475_433314_1_1695625132520.pdf (Chinese) (25 September 2023; retrieved 2 August 2026)
• Government press release, "SHMH officiates at launch ceremony of Chronic Disease Co-Care Pilot Scheme" (launch on 13 November 2023; the Secretary's remarks on relieving public sector pressure): https://www.info.gov.hk/gia/general/202311/13/P2023111300228.htm (English) and https://www.info.gov.hk/gia/general/202311/13/P2023111300227.htm (Chinese) (13 November 2023; retrieved 2 August 2026)
• Legislative Council Panel on Health Services paper, "Update on Chronic Disease Co-Care Pilot Scheme", LC Paper No. CB(4)547/2024(03) (launched 13 November 2023 for three years; participation and screening figures as at 2 May 2024): https://www.legco.gov.hk/yr2024/english/panels/hs/papers/hs20240510cb4-547-3-e.pdf (for discussion on 10 May 2024; both language versions exist and this article reports the facts in the English version; retrieved 2 August 2026)
• Government press release, opening remarks by the Secretary for Health on the Chronic Disease Co-Care Pilot Scheme (13 bi-directional referrals and the outcome for 2 of them; the speech's own correction of 6 000 to 8 000): https://www.info.gov.hk/gia/general/202405/10/P2024051000416.htm (10 May 2024; this release exists in Chinese only; retrieved 2 August 2026)
• Government press release, participating clinics begin offering direct enrolment (direct enrolment at clinics from 25 March 2024): https://www.info.gov.hk/gia/general/202403/25/P2024032500488.htm (25 March 2024; retrieved 2 August 2026)
• Government press release (9 August 2024, the drug list expansion and the annual adjustment mechanism for consultation co-payments; 473 of 718 service points at $150 or below): https://www.info.gov.hk/gia/general/202408/09/P2024080900236.htm (English) and https://www.info.gov.hk/gia/general/202408/09/P2024080900234.htm (Chinese) (9 August 2024; retrieved 2 August 2026)
• Government press release (20 March 2025, blood lipid testing added from 28 March 2025; participation and screening figures as at 12 March 2025): https://www.info.gov.hk/gia/general/202503/20/P2025032000224.htm (English) and https://www.info.gov.hk/gia/general/202503/20/P2025032000216.htm (Chinese) (20 March 2025; retrieved 2 August 2026)
• Government press release, the Health Bureau's response to enquiries about the Chronic Disease Co-Care Pilot Scheme (the commissioned university research, the six-month changes in HbA1c and systolic pressure, the 614-participant questionnaire results; participation as at 23 July 2025; the phased arrangement at designated Hospital Authority general out-patient clinics): https://www.info.gov.hk/gia/general/202508/01/P2025080100915.htm (English) and https://www.info.gov.hk/gia/general/202508/01/P2025080100866.htm (Chinese) (1 August 2025; retrieved 2 August 2026)
• Government press release (28 August 2025, the annual co-payment adjustment and the extension of who the scheme serves; the sentence placing "not more than $120" beside the treatment phase; 617 of 971 service points and the median of $150; the 3.1 per cent increase; 874 service points unchanged; the comparison with the GOPC PPP Programme, which has about 50,000 participants and is expected to end in 2028): https://www.info.gov.hk/gia/general/202508/28/P2025082800552.htm (English) and https://www.info.gov.hk/gia/general/202508/28/P2025082800547.htm (Chinese) (28 August 2025; retrieved 2 August 2026)
• Government press release, "Primary Healthcare Commission launches Hepatitis B Co-care Scheme…" (launched 7 February 2026; the $180 screening co-payment and $136 for up to two consultations; the $166 treatment-phase consultation subsidy confirmed again; the hepatitis B workflow and the second blood test six months later; consultation co-payments having to be consistent with the CDCC scheme; the extra $300 a year for managing both; one consultation, one co-payment; the 18 designated family medicine clinics and the waiver arrangement): https://www.info.gov.hk/gia/general/202601/26/P2026012600288.htm (English) and https://www.info.gov.hk/gia/general/202601/26/P2026012600284.htm (Chinese) (26 January 2026; retrieved 2 August 2026)
• Government press release, the Secretary for Health officiates at the opening of the Yau Tsim Mong District Health Centre and the launch of the Primary Healthcare Co-care Network (regularisation and renaming; a five-year first stage of the Primary Healthcare Co-care Network targeting about 700,000 people; participation as at the end of January 2026; the 12-month HbA1c and systolic pressure figures; the 200,000-participant simulated scenario): https://www.info.gov.hk/gia/general/202603/13/P2026031300680.htm (English) and https://www.info.gov.hk/gia/general/202603/13/P2026031300531.htm (Chinese) (13 March 2026; retrieved 2 August 2026)
• Government press release, the Government establishes the Primary Healthcare Commission: https://www.info.gov.hk/gia/general/202407/15/P2024071500326.htm (15 July 2024; retrieved 2 August 2026)
• Elderly Health Care Voucher Scheme, "Eligible Elderly Persons and Annual Voucher Amount" (eligibility at 65 or above; $2,000 a year with an accumulation limit of $8,000): https://www.hcv.gov.hk/tc/hcvs/service_area.html and https://www.hcv.gov.hk/en/hcvs/service_area.html (no revision date on the page; retrieved 3 August 2026)
• Hospital Authority, "Fees and Charges" (public charges for eligible persons: $150 per attendance at a family medicine clinic and $5 per drug item, each charging unit covering 4 weeks; pathology service charges): https://www.ha.org.hk/visitor/ha_view_content.asp?Content_ID=10045&Lang=CHIB5&Dimension=100&Ver=HTML and the same URL in English with Lang=ENG (the page states an effective date of 1 January 2026; retrieved 1 August 2026)
• Hospital Authority, "Annual Fee Cap" (for eligible persons) (no financial assessment required, the four conditions, application through HA Go or a hospital shroff office, re-application each calendar year, the deadline of 31 March of the following year with late applications not accepted, and the exclusion of self-financed drugs and medical devices): https://www.ha.org.hk/visitor/ha_view_content.asp?Content_ID=281820&Lang=CHIB5&Dimension=100&Ver=HTML and the same URL in English with Lang=ENG (effective 1 January 2026; retrieved 1 August 2026)

---

This article was written from the official sources listed above; information date 2 August 2026. This scheme's charges and eligibility conditions are adjusted by the Government administratively, and the scheme website's current publication governs. Whether you should join, what medicine you should take, which doctor you should choose — this article does not answer; those are for you and your doctor.

---

#Further reading

• On this platform: Hypertension
• On this platform: High cholesterol
• On this platform: Public hospital charges from 2026
• Primary Healthcare Commission CDCC official pages: primaryhealthcare.gov.hk/cdcc
• Government press release — CDCC service extension (2025-08-28, Chinese version): info.gov.hk

This article is health education information only and contains no pharmaceutical advertising. This platform neither promotes nor recommends any particular medicine, treatment or medical device for the conditions above.

Disclaimer